By Dean Seal


Shares of Immuneering rose after the company received a regulatory fast-track designation for IMM-1-104, its treatment for pancreatic ductal adenocarcinoma

The stock was up 13% at $7.49 in premarket trading. Shares had fallen 10% year-to-date when the market closed last week.

The clinical-stage oncology company said Tuesday that the Food and Drug Administration granted the designation to IMM-1-104 for patients with pancreatic ductal adenocarcinoma who have failed one line of treatment.

The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

02-20-24 0853ET